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Abstract 
Burkitt lymphoma has provided a model for the understanding of the epidemiology, the molecular abnormalities that induce tumours, and 
the treatment of other lymphomas. It is important to remember that the early phases of this work were conducted in Africa where today, 
unfortunately, the disease usually results in death because of limited resources, even though most children in more developed countries 
are cured. This must be changed. In addition, it is time to re-explore, with modern techniques, some of the questions that were raised 
some 50 years ago shortly after Burkitt’s first description, as well as new questions that can be asked only in the light of modern 
understanding of the immune system and the molecular basis of tumor development. The African lymphoma has taught us much, but 
there is a great deal still to be learned. 
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Discovery of the tumour 
Denis Parsons Burkitt was born in 1911 in Enniskillen, the 
picturesque county town of Fermanagh, now in Northern 
Ireland. ‘Enniskillen’ is derived from a Gaelic word meaning 
Ceithleann's island, the town being situated on an island 
between two loughs (lakes) connected by the River Erne. 
According to Irish mythology, Ceithleann was the wife of Balor, 
the one-eyed king of a race of giants—a mythology that has 
echoes in Burkitt's life. Sadly, at the age of 11, young Denis 
suffered an injury that led to the loss of an eye. Although this 
hampered his eyesight and, to a degree, his subsequent career 
as a surgeon, it had no effect on his insight. Burkitt doubtless 
inherited some of his observational skills from his father, James 
Parsons Burkitt, a civil engineer, but also an amateur 
ornithologist who was one of the first to use the technique of 
ringing or banding to recognize individual birds, allowing him to 
meticulously map their territories. James Burkitt's maps must 
have impressed his elder son, who was later to map the 
distribution of the 'African lymphoma' (Figure 2). 
Denis Burkitt attended the Portara Royal School at Enniskillen, 
one of five free schools founded by Royal Charter in 1608 by 
King James I. 
In this respect, he followed in the footsteps of two Irish literary 
giants, Oscar Wilde and Samuel Beckett, who, like Burkitt, also 
continued their education at Trinity College, Dublin. Burkitt, 
without a clear idea of his future, had taken up engineering at 
Trinity College. He joined the University Christian Society, which 
gave new meaning to his life; he decided that his calling was to 
become a missionary. This, perhaps coupled to sharing a room 
with a medical student, led him to give up his engineering 
studies and instead take up medicine. After completing his 
studies, he decided to become a surgeon—somewhat 
surprising, perhaps, in view of his lack of binocular vision—and 
completed his basic training shortly before World War II. 
Burkitt took a position as ship's doctor before applying for a post 
in the colonial medical services. Unfortunately, he was turned 
down because he had only one eye. After other unsuccessful 
applications for an overseas posting, he decided to join the 
Army Medical Corps and, after working in England for a while, 
was sent to Africa, where he served in Somalia and Kenya. 
Once he spent leave in Uganda and visited the old Mengo 
Hospital, where the first missionary doctor to Africa, Sir Albert 
Cook, had worked, as well as the Mulago Teaching Hospital in 
Kampala, where he himself would later work. This experience,
coupled to his evangelical zeal—and possibly the example of 
his uncle Roland, who practiced surgery in Nairobi—convinced 
him that he was destined to serve in Africa. In 1946, Burkitt 
again applied to the British Colonial Office for a post. This time 
he was accepted and was appointed to the position of District 
Medical Officer in Lira, a small town in the Northern Lango 
district of Uganda. While there he noted a high incidence of 
hydrocele, caused by mosquito-born filarial worms that block 
lymphatic vessels, and was able to show that the incidence was 
much higher in the eastern part of Lango (30% of men) than the 
western region (1%) [1]. This experience, too, must have 
sensitized him to geographic epidemiology while impressing 
upon him the important role of arthropod vectors in transmitting 
disease in Africa—a lesson that served him in good stead in the 
context of the African lymphoma. 
Burkitt had been in Lira for only 18 months when he received a 
telegram summoning him to Mulago Hospital (Figure 5), where 
Ian McAdam, the only other formally trained surgeon in Uganda 
at the time, had become ill. McAdam, who subsequently 
became the head of the department of surgery in the University 
Hospital, was to become a strong supporter of Burkitt's 
subsequent work. 
It was not until 1957 that Burkitt saw his first case of multiple 
jaw tumours (i.e. bilateral maxillae and mandibles) in a five-
year-old boy he was asked to see in the children’s ward at 
Mulago Hospital by the pediatrician, Hugh Trowell. A biopsy 
report described the tumour as a ‘small round cell sarcoma’. 
Burkitt was unable to offer any advice on treatment, although 
the gross facial distortions caused by the jaw tumours made a 
big impression on him. Shortly afterwards he saw a second 
child, with tumour in all four jaw quadrants, during a regular visit 
to a hospital in Jinja, a small town situated where the river Nile 
flows out of Lake Victoria (one of the illusive sources of the Nile 
sought by the European explorers, Burton and Speke). This 
second child also had tumours in the abdomen. Like the first, 
his disease had been diagnosed as a small round cell sarcoma. 
The coincidence of seeing two children with jaw tumours in 
quick succession led Burkitt to examine the records of other 
patients seen in Mulago Hospital. He identified 29 other children 
who had presented with jaw tumours, although many, like the 
child in Jinja, had additional disease at other sites, including the 
orbit and abdomen, salivary glands, nervous system and 
elsewhere (Figure 3). Most of these tumours were diagnosed as 
small round cell tumours and variably reported, according to the 
sites of disease, as sarcoma, retinoblastoma, germinoblastoma, 
Ewing's sarcoma, Wilms' tumour or neuroblastoma. 




















Figure 1: Lake Victoria, Uganda. The regions surrounding the lake are high-incidence regions for Burkitt lymphoma. Picture from Wikipedia 
Commons taken by D Luchetti. 
 
Figure 2: Map of Africa showing the 'lymphoma belt' in which Burkitt lymphoma occurs at high incidence. Lower incidence areas (e.g. 
highlands) within this zone are not shown. 




















Figure 3: Children with Burkitt lymphoma showing multiple disease sites. 
 
Figure 4: Age distribution of Burkitt lymphoma in Africa (a) and the United States (b). Jaw and orbital tumours are particularly common in 
young children in African Burkitt lymphoma (fraction of patients with jaw tumours is indicated by the red column in (a)) but not in Burkitt 
lymphoma in the United States.






















Figure 5: Staff of the Lymphoma Treatment Center in the Mulago Hospital complex in the early 1970s towards the end of the period of 
collaboration between Makerere University and the National Cancer Institute.
Although several European pathologists working in Africa had 
observed the high incidence of jaw tumours, and of lymphomas 
in children with cancer many years before Burkitt saw his first 
case [2–5], Burkitt was the first to describe the clinical 
syndrome. He proposed that all the children with jaw tumours, 
regardless of other sites of disease, were probably suffering 
from the same disease. His first paper, entitled ‘A sarcoma 
involving the jaws of African Children’ was published in the 
British Journal of Surgery in 1958 [6]. This aroused little interest, 
since the disease offered limited scope for surgery. However, 
unknown to Burkitt, Gregory O'Conor and Jack Davies, 
pathologists also working at Mulago Hospital, were in the 
process of surveying the malignant tumours in children in the 
Mulago Hospital Registry that had been initiated seven years 
before. In fact, Davies had earlier observed that approximately 
half of the childhood tumours were derived from the 'reticulo-
endothelial system' [7] and O'Conor and Davies’ more extensive 
review, which included children without jaw tumours, confirmed 
this [8]. It soon became clear that the tumour described by 
Burkitt was a lymphoma and, in 1961, Burkitt and O'Conor 
published additional papers in the journal Cancer, bringing it to 
the attention of cancer specialists [9,10]. Although it seemed 
initially that the tumour was confined to Africa, it was 
subsequently recognized that histologically identical lymphomas 
occur throughout the world, although at a much lower incidence 
[11–15] and with some differences at clinical and molecular 
levels from the African lymphoma [16]. 
The relationship of Burkitt lymphoma to acute lymphoblastic 
leukaemia (ALL) was frequently discussed since the latter 
disease was rarely seen in Africa. Dalldorf reported in 1962 that 
ALL, the commonest childhood malignancy in the USA, was the 
least common in East Africa, accounting for only 1–3% of 
childhood cancers in several published series [17]. ALL remains 
uncommon in equatorial Africa today—but that is another story. 
 
Discovery of Epstein-Barr virus 
A few months after the publication of Burkitt's first paper, Dr 
Oettle, a cancer specialist from South Africa, visited Kampala, 
and Burkitt was intrigued to learn from him that he had never 


















seen children with a similar clinical syndrome in South Africa. 
This observation, influenced perhaps by his earlier work on 
hydrocele, led Burkitt to think about the geographical distribution 
of the tumour. Was it widespread throughout Africa, or confined 
to certain regions? Burkitt hung a map of Africa on the wall of 
his office and started to indicate places where children with jaw 
tumours had been seen. He sent 1000 brochures to government 
and mission hospitals throughout Africa and started to plot the 
'lymphoma belt', as shown in Figure 2. By now, several 
research organizations were interested in the tumour, and 
Burkitt was given several grants, totalling £700, which enabled 
himself and two friends, Ted Williams and Cliff Nelson, both 
missionary doctors, to undertake a safari to define the southern 
limit of the high-incidence zone on the eastern side of Africa. 
Burkitt and his co-researchers set off from Kampala on 7 
October 1961 in the 1954 Ford Station Wagon and returned ten 
weeks later, having visited some 57 hospitals in eight countries 
and travelled 10,000 miles. Although imprecise by today's 
standards, the characteristic jaw tumours provided a powerful 
marker of the occurrence of the tumour, and Burkitt and his co-
researchers were able to show that the 'tumour belt’ extended to 
Lourenco Marques in southern Mozambique. Having defined in 
some detail the high-incidence regions, it appeared that in east 
Africa, at least, the barrier to the occurrence of Burkitt 
lymphoma was altitude [18,19]. Burkitt discussed this with 
Alexander Haddow, the director of the East African Virus 
Research Institute in Entebbe. 
Haddow studied Burkitt's map and pointed out that the altitude 
barrier occurred at 5000 ft at the equator (which passes through 
Uganda) and became progressively lower with the distance 
from the equator [20]. This strongly suggested that temperature 
rather than altitude constituted the true barrier, as had already 
been shown for a number of insect-born diseases, particularly 
those vectored by mosquitoes. Additional visits by air to 
Rwanda, Burundi, Kinshasa (Leopoldville at the time), Nigeria 
and Ghana confirmed the importance of altitude/temperature 
but also led to the recognition that low-lying areas where the 
tumour did not occur were arid regions, such as Kano in 
southern Nigeria. It seemed that the tumour was common in 
regions with temperatures that did not fall below 60°F, as long 
as there were at least 20 inches of rainfall per year—conditions 
required for mosquitoes to breed. 
On seeing Burkitt's new, improved map, Haddow confirmed that 
the distribution of the tumour conformed closely to the 
distribution of number of diseases known to be transmitted by 
insects, including trypanosomiasis (sleeping sickness), yellow 
fever and the recently recognized O'Nyong-Nyong. The findings 
seemed to be consistent with earlier research, particularly in the 
United States, that had demonstrated that malignancies in 
animals, particularly sarcomas and leukaemia, could be 
transmitted by viruses, although no one, at that time, had 
succeeded in identifying a human tumour virus. 
Meanwhile, Burkitt had been receiving many invitations to 
speak. One of his lectures, given at the Middlesex Hospital in 
London in March 1961, was attended by a pathologist interested 
in virology, Michael Anthony Epstein. Impressed with the 
possibility that the lymphoma could be caused by a mosquito-
vectored virus, Epstein approached Burkitt after the lecture and 
asked him to send some tumour samples to London in order to 
search by electron microscopy for virus particles in the tumour 
cells. Initial studies of tumour cells flown in from Uganda were 
negative, but Epstein and Barr succeeded in developing several 
continuously growing cell lines from the tumour cells. In the first 
of these, Epstein Barr-1 (EB1), Epstein et al were able to 
identify herpes-like virus particles in a small fraction of the cells. 
Unable to demonstrate reactivity with sera derived from patients 
known to be infected with other herpesviruses, it was clear that 
this was a previously undescribed virus and potentially the first 
human tumour virus. The report of their discovery was 
published in 1964 just a few years after the recognition of the 
unusual distribution of the African lymphoma [21]. 
It was soon shown that the virus associated with almost all 
African Burkitt lymphomas is ubiquitous, infecting almost the 
entire adult global population, although patients with African 
Burkitt lymphoma had a significantly higher antibody titre to the 
EBV virus capsid antigen (VCA) than controls [22]. The 
epidemiological relationship of EBV to Burkitt lymphoma was 
further demonstrated in a large serological study carried out by 
Geser et al in the West Nile district of Uganda. Starting in 1972, 
42,000 children were bled between the ages of six months and 
two years and followed until March 1979 for the development of 
Burkitt lymphoma. In this time, 16 patients with Burkitt 
lymphoma were identified in whom a prior serum sample was 
available. Antibodies to the EBV VCA were also shown to be 
significantly higher in these patients in the pre-tumour sample 
[23]. This study demonstrated the very early infection with EBV 
in all of the children, showed that EBV infection can occur years 
before EBV-associated Burkitt lymphoma develops and was at 
least consistent with a causal role for the virus. 
It has subsequently become clear that all tumour cells (and 
derived cell lines) in African Burkitt lymphoma contain multiple 
copies of the EBV genome, although the viral genome is 
present in only 1–10 per million circulating B lymphocytes (B 
lymphocytes, which are involved in antibody production, are the 
cell lineage in which EBV persists throughout life) [24,25]. This 


















also suggests an important role for EBV, since African Burkitt 
lymphoma clearly occurs preferentially in the small fraction of 
EBV-containing B-cells in the body. 
It was also demonstrated that EBV can 'transform' resting B 
cells into large proliferating cells, suggesting that EBV could be 
the driving force to the growth of Burkitt lymphoma. This proved 
to be wrong, however, for although EBV can 'immortalize' 
normal B lymphocytes in vitro and induce them to proliferate, in 
doing so it expresses nine viral genes (so-called latent genes) 
whereas only one of these genes, Epstein Barr virus nuclear 
antigen 1 (EBNA-1), along with some untranslated RNA 
molecules, are expressed in Burkitt lymphoma [24,25]. EBNA-1 
is known now to be responsible for the replication of the viral 
genome, and for maintenance of the same number of genome 
copies in daughter cells. It does not drive proliferation. Actual 
virus is rarely produced in tumour cells because it is associated 
with cell disruption (lysis), allowing virus to escape and infect 
other cells or other people (an essential part of its life cycle). 
Thus, cell lines or tumours could not survive and the virus would 
not persist throughout life if all infected cells produced virus. We 
now have a detailed understanding of the structure and function 
of various EBV proteins, but the precise mechanism(s) whereby 
EBV contributes to the development of Burkitt lymphoma 
remains ill-defined [25]. 
 
A role for malaria 
The geographical studies carried out by Burkitt and others 
suggested to most that the African lymphoma was a rare 
manifestation of a common virus infection transmitted by 
mosquitoes. The subsequent discovery of EBV seemed to 
confirm this. However, it is now known that EBV is not 
transmitted by mosquitoes, but via saliva. In societies of low 
socio-economic status, there are many opportunities for saliva 
exchange, particularly mothers to infants. For example, in the 
absence of pureed baby foods, mothers often pre-chew the food 
they give to their infants during the weaning process. Thus, EBV 
infection, which in any case occurs throughout the world, cannot 
explain the high-frequency zone of Burkitt lymphoma in Africa. 
Interestingly, in the same year that EBV was discovered (1964), 
another explanation for the climatically determined distribution 
of Burkitt lymphoma was suggested—malaria. This possibility, 
first expressed in print by Gilbert Dalldorf, a microbiologist from 
Sloan-Kettering Institute in New York, had been heavily 
overshadowed by the vectored-virus hypothesis. By now, 
Burkitt's enquiries had established that the tumour was also 
common in Papua New Guinea [26], and Dalldorf, in a detailed 
epidemiological study [27], pointed out that malaria was 
holoendemic in both equatorial Africa and New Guinea, and that 
repeated infections were nearly universal in the first year of life 
with variation in the intensity of infection being related to 
temperature and rainfall, which influence the breeding of 
mosquito vectors (Anopheles species) of malaria. He noted that 
in Kenya, the highest incidence rates of holoendemic malaria 
and the African lymphoma occur in identical areas—along the 
coast of the Indian Ocean and the shores of Lake Victoria. In 
1965 Goma presented evidence based on extensive surveys in 
two districts in Uganda that Burkitt lymphoma tends to occur in 
communities which are very close (within a mile) to permanent 
or semi-permanent surface water, whether in the form of 
swamps or lake edges, where mosquitoes breed [28]. This 
doubtless explains why Burkitt lymphoma has a higher 
frequency in rural regions. 
Burkitt and others began to explore the malaria (or 'alternative') 
hypothesis and made a number of tantalizing observations [29]. 
In the islands of Zanzibar and Pemba off the coast of Tanzania, 
and Leopoldville (now Kinshasa), intensive malarial eradication 
programs (directed at mosquitoes) had dramatically reduced the 
frequency of malaria (from 70% to less than 5%). In each case, 
in spite of the favourable climatic characteristics, Burkitt 
lymphoma had not been reported. Since then (in the case of 
Zanzibar, since 1964), the DDT-based eradication programs 
have been halted and malaria has returned to these regions—
along with Burkitt lymphoma. In a meeting held by the 
International Union Against Cancer in 1967, Barnley pointed out 
that topography also influences the ecology of arthropods [30]. 
Steep river valley slopes, for example are not conducive to the 
persistence of temporary rain pools fully exposed to the heat of 
the sun, which are the preferred breeding places for Anopheles 
gambiae mosquitoes, and are generally devoid of malaria. He 
also stated that large bodies of fresh water (such as Lake 
Victoria) provide the major breeding grounds for Anopheles 
funestus. These findings were consistent with a role for a 
disease born by anopheline mosquitoes, but did not prove that 
malaria was the disease in question, although the positive 
relationship between the intensity of malarial infection and the 
occurrence of Burkitt lymphoma, a strong supporting argument, 
has been confirmed by a number of studies in both east and 
west Africa [31–34]. It has also been shown that in patients with 
acute malaria, the fraction of circulating lymphocytes containing 
EBV is increased in normal individuals, most probably as a 
result of impaired T-cell immunity, providing at least one 
mechanism whereby EBV and malaria can collaborate in the 
pathogenesis of Burkitt lymphoma [35–39]. 


















Table 1: Cases of Burkitt lymphoma recorded in the North Mara District of Tanzania in three sequential time periods. Chloroquine prophylaxis 
was given in the middle period. 
In an attempt to demonstrate a role for malaria directly, Geser et 
al conducted clinical studies in the North Mara district of 
Tanzania designed to study the role of malaria directly [40]. In 
this region, active searching for cases of Burkitt lymphoma had 
been ongoing since 1970, permitting the measurement of 
incidence rates, along with surveys of malaria parasitemia and 
antibody levels). With this background information in hand, 
malaria prophylaxis (using a dose of chloroquine every two 
weeks) was initiated in all children aged one to ten years for a 
period of five years (1977–82). The incidence of malaria 
parasitemia initially fell to the lowest levels ever recorded, and 
the incidence of Burkitt lymphoma also dropped considerably 
(from four to less than one per 100,000 per year) and remained 
statistically significantly lower throughout the five-year period, 
beginning to rise only after the discontinuation of chloroquine 
prophylaxis (Table 1). However, the drop in incidence appeared 
to have begun prior to the administration of malaria prophylaxis, 
although this did not reach statistical significance. This could 
have been by chance alone, since the relatively small 
population of people in the North Mara lowlands where the trial 
took place—approximately 140,000 at the beginning of the 
study—is likely to result in a somewhat unstable annual 
incidence rate, although rates as low as those observed during 
the period of prophylaxis had not been seen in the course of a 
13-year observation period before the start of the trial. In 
addition, it was found that there were defects in the system of 
distribution of chloroquine, which presumably accounted for the 
increase in parasitemia rates that began after only two years of 
prophylaxis. Thus, although these results are very suggestive of 
a role for malaria in the genesis of African Burkitt lymphoma, 
they are generally not considered to be definitive. 
 
Characteristic chromosomal translocations 
and the development of Burkitt lymphoma 
In 1975, a characteristic chromosomal translocation (t8;14) was 
discovered by Zech et al in Burkitt lymphoma [41]. Subsequent 
molecular studies in the 1980s demonstrated that this and 
related 'variant' translocations resulted in the juxtaposition of an 
immunoglobulin gene (the genes responsible for the production 
of antibodies) to an oncogene called MYC—a gene heavily 
involved in a variety of critical cellular pathways including 
growth and programmed cell death (apoptosis). After many 
years of research, it is now believed that the ectopic 
(inappropriate) expression of MYC in B cells undergoing an 
immune response, most often caused by regulatory elements in 
the adjacent, translocated immunoglobulin gene, is the principle 
cause of the rapid, uncontrolled growth of Burkitt lymphoma 
cells. A number of reviews on this topic, which will not be 
discussed here, have been published [42–50]. 
Overall, the evidence suggests that at least one mosquito-borne 
disease, most probably malaria, predisposes to the 
development of Burkitt lymphoma. Malaria causes profound 
hyperplasia (overgrowth) of B lymphocytes—the cell lineage 
from which Burkitt lymphoma is derived. 
It also results in an increase in the proportion of circulating 
memory B cells infected by EBV, strongly suggesting that the 
total body burden of EBV is also increased. This could result in 
an increased likelihood of the occurrence of the specific 
chromosomal translocations that are the proximate cause of 
Burkitt lymphoma. EBV probably also contributes directly to the 
development of the tumour, perhaps by inhibiting cell death by 
apoptosis, which would otherwise be induced by the 
inappropriate expression of MYC. 
 
Discovery of the response to 
chemotherapeutic agents 
While the epidemiological questions raised by the observations 
made in Africa were intriguing, Burkitt and other clinicians in 
Africa were faced with the pragmatic problem of managing 
children with this disease. 
Surgery was hardly an option—even on the rare occasions 
when tumour could be entirely removed, regrowth almost 
always occurred. 
Radiotherapy was not then available in equatorial Africa (even 
now there are very few radiotherapy facilities in this region), but 


















by the late 1950s a number of chemotherapeutic agents had 
become available and several were known to be particularly 
active in childhood ALL. It was clearly of considerable interest to 
know whether Burkitt lymphoma responded to chemotherapy. 
Joseph Burchenal, a pioneer chemotherapist working at the 
(then) Sloan-Kettering Institute for Cancer Research in New 
York, visited Burkitt in Uganda in 1960 and persuaded him to 
administer methotrexate, one of the drugs Burchenal had been 
working on in the context of ALL, to two children with Burkitt 
lymphoma. In both cases, a single dose induced dramatic 
tumour regression. This experience encouraged Burkitt to try 
other drugs, including cyclophosphamide. 
Subsequently, investigators in Africa, including Burkitt in 
Uganda, Clifford in Kenya and Ngu in Nigeria, aided by western 
experts in chemotherapy, such as Oettgen and Burchenal from 
the Sloan-Kettering Institute for Cancer Research in New York, 
and David Galton from the Chester Beatty Institute in London, 
collaborated in documenting the response of Burkitt lymphoma 
to various chemotherapeutic drugs, often donated by the 
pharmaceutical industry (treatment studies are reviewed in 
[24,51,52]). Although these studies were not conducted in the 
disciplined way in which clinical trials are carried out today, and 
a significant fraction of patients was lost to follow-up, they led to 
the clear demonstration that Burkitt lymphoma was responsive 
to a broad range of chemotherapeutic agents. Burkitt, Clifford 
and Ngu reported some astonishing apparent cures with 
minimal therapy (several years of disease-free survival after 
only one or two cycles of therapy). In Burkitt's series of 90 
patients with jaw tumours treated at Mulago Hospital, Uganda, 
74, or 82%, of the 90 patients had a good response. 
Complete, durable remissions were observed with all three 
agents, although response depended upon the tumour size.
Burkitt also noted that recurrent disease, whether at the same 
or different sites, did not occur after 11 months of remission, 
that is, patients free of disease at this time could be considered 
cured. 
These early results laid the foundation for subsequent studies. 
Notable among these were clinical trials conducted in Uganda 
as part of a co-operative agreement between the National 
Cancer Institute of the USA and the University of Makerere in 
Kampala, Uganda (Figure 5). The emphasis eventually moved 
to drug combinations based on the most active drugs identified 
that led to a combination known as cyclophosphamide, 
vincristine and methotrexate (COM), which is the foundation of 
INCTR's ongoing studies in the treatment of African Burkitt 
lymphoma (including AIDS-associated Burkitt lymphoma). In the 
United States and Europe, much more intensive drug 
combinations have since been developed, which have resulted 
in overall survival rates in the region of 90% [53]. 
Burkitt lymphoma has provided a model for the understanding of 
the epidemiology, the molecular abnormalities that induce 
tumours and the treatment of other lymphomas. It is important 
to remember that the early phases of this work were conducted 
in Africa where today, unfortunately, the disease usually results 
in death because of limited resources, even though most 
children in more developed countries are cured. This must be 
changed. In addition, it is time to re-explore, with modern 
techniques, some of the questions that were raised some 50 
years ago shortly after Burkitt's first description, as well as new 
questions that can be asked only in the light of modern 
understanding of the immune system and the molecular basis of 
tumour development. 
The African lymphoma has taught us much, but there is a great 
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